Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients
Source : https://www.frontiersin.org/articles/10.3389/fneur.2022.961628/full
We previously found that leflunomide combined with low-dose prednisone rapidly improved the clinical symptoms of myasthenia gravis (MG), but we had not investigated the mechanism of this phenomenon. This study...
Relevance: We previously found that leflunomide combined with low-dose prednisone rapidly improved the clinical symptoms of myasthenia gravis (MG), but we had not investigated the mechanism of this phenomenon. This study documents the effect of leflunomide combined with low-dose prednisone on pro-inflammatory T cells in MG patients.
Myasthenia Gravis Complicated by Eosinophilic Granulomatosis with Polyangiitis: A Case Report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386410/
A 55-year-old woman with a history of allergic sinusitis was being administered cyclosporine for ptosis and diplopia due to myasthenia gravis since age 46 years. She developed painful dysesthesia that...
Conclusion/Relevance: In patients with myasthenia gravis having a history of allergic diseases, considering EGPA as a complication and monitoring prior changes in blood data are necessary for early detection before apparent tissue damage.
Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol
Source : https://bmjopen.bmj.com/content/12/9/e060259
Objective We aim to systematically assess the clinical characteristics of ocular myasthenia gravis (OMG) and report on the proportion of patients who develop secondary generalised myasthenia gravis (SGMG). Introduction OMG...
Objective: We aim to systematically assess the clinical characteristics of ocular myasthenia gravis (OMG) and report on the proportion of patients who develop secondary generalised myasthenia gravis (SGMG).
Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.968206/full
Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG...
Conclusion/Relevance: To enable identification of MG patients that are likely to respond to C7 inhibition, we developed a patient stratification assay and showed in a small cohort of MG patients (n=19) that 63% had significant complement activation and C7-dependent loss of AChRs in this in vitro set up. This study provides validation of C7 as a...
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
Source : https://www.tandfonline.com/doi/abs/10.1080/1744666X.2022.2106972?journalCode=ierm20
ABSTRACT Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day. Efgartigimod is a human IgG1-derived Fc fragment modified at...
Expert Opinion: Efgartigimod was efficacious and safe for generalized myasthenia patients with AChR antibody-positive patients. These findings need to be confirmed in AChR antibody-negative patients, and long-term safety studies are currently ongoing.